Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
- None.
- None.
Insights
The initiation of the development of Cloudscreen 2.0 by Cosmos Health marks a significant stride in the biotechnology and pharmaceutical sectors. The platform's ability to leverage advanced AI and machine learning technologies for drug repurposing is particularly noteworthy. Drug repurposing, which involves finding new therapeutic uses for existing drugs, can dramatically reduce the time and cost associated with drug development. By utilizing AI for drug-protein interaction predictions, Cloudscreen 2.0 could potentially enhance the efficiency of this process.
From an investment perspective, the success of such a platform could lead to a reduction in R&D expenditures and a quicker path to market for new applications of existing drugs. This has the potential to create a competitive edge for Cosmos Health, as it could result in new patents and product launches. However, the actual impact will depend on the platform's accuracy and the ability to translate its findings into viable commercial products. The mention of using datasets that are significantly larger than those used in the original Cloudscreen suggests an improvement in the predictive capabilities of the platform, which could be a game-changer if proven effective.
As the healthcare industry continues to embrace digital transformation, the development of Cloudscreen 2.0 by Cosmos Health could be seen as a strategic move to stay at the forefront of healthcare innovation. The platform's use of deep learning models and graph embedding techniques to predict interactions across the human proteome is a testament to the evolving role of computational methods in drug discovery.
Investors should consider the potential long-term benefits of integrating such technologies into the healthcare ecosystem. A successful AI-driven repurposing platform can lead to a paradigm shift in the way diseases are treated, with a focus on personalized medicine, especially considering the integration of mutagenesis data for specific populations. The ability to predict disordered protein interactions, which are important in many diseases, could open up new avenues for treatment. The scalability promised by the upgraded infrastructure, including GPU cloud services, is also critical as it suggests the platform's capability to handle vast amounts of data, which is essential for the complex task of drug repurposing.
The announcement of Cloudscreen 2.0's development could influence investor sentiment towards Cosmos Health. The pharmaceutical market is highly competitive and companies that invest in innovative R&D platforms such as Cloudscreen 2.0 can potentially reap substantial rewards. Investors will be looking for indicators of the platform's commercial viability and its ability to generate a return on investment through new discoveries and marketable patents.
While the future looks promising, it is important to consider the risks associated with such ventures. The success of Cloudscreen 2.0 is not guaranteed and the costs involved in its development and implementation could be substantial. Additionally, there may be regulatory hurdles to overcome when bringing repurposed drugs to market. Nevertheless, if Cosmos Health can successfully leverage Cloudscreen 2.0 to identify and patent new drug applications, they could secure a significant portion of the market share and potentially disrupt traditional drug discovery processes.
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.
As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a significant leap forward in computational predictions for drug repurposing, aiming to unlock unknown actions of existing drugs on the market.
With the integration of cutting-edge AI and machine learning technologies, Cloudscreen 2.0 builds on successful drug-protein interaction prediction algorithms, using advanced deep learning models and graph embedding techniques. It aims to predict interactions across the human proteome's complete structural landscape. Furthermore, mutagenesis data for specific populations or diseases will be integrated, along with prediction tools for disordered proteins, which have emerged as significant players in several disease phenotypes.
Significant improvements in prediction methods are expected to result from utilizing datasets of chemical and biological data that are over 100 times larger than those used in the original platform, with the goal of creating more robust predictions and achieving higher confidence scores. The updated planned infrastructure, in addition to Graphics Processing Unit (GPU) cloud services, will enable the scaling up to such amounts of data with updated prediction capabilities, setting a new standard for AI approaches in drug repurposing.
The integration of AI not only accelerates the identification of new therapeutic uses for existing drugs, but also enhances our current comprehension of the molecular underpinnings of drug action and disease mechanisms.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We are extremely excited to launch Cloudscreen 2.0, which elevates our R&D efforts to new heights. By integrating AI and machine learning technologies with drug repurposing, we are confident that we possess the necessary tools to maximize the likelihood of success in new discoveries, patents, and product launches. Consequently, positive outcomes from Cloudscreen 2.0 could have a game-changing impact on Cosmos."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.cloudscreen.gr, and www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What is Cosmos Health Inc. developing?
When did Cosmos Health complete the acquisition of Cloudscreen?
What technologies are being utilized in Cloudscreen 2.0?
What is the goal of Cloudscreen 2.0?
Who is the CEO of Cosmos Health?
